Brought to you by 
Yumanity Therapeutics closes $45mm Series A round
12 Jan 2022
Executive Summary
Yumanity Therapeutics (neurodegenerative disease therapeutics) raised $45mm in its Series A round led by Fidelity Management & Research Co. Other investors included Redmile Group (a participant in its 2015 seed funding), Alexandria Venture Investments, Biogen Inc., Sanofi-Genzyme BioVentures, and Dolby Family Ventures. One executive from Biogen and one from Alexandria joined the board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Yumanity Therapeutics closes $45mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice